Hangzhou Tigermed Consulting (300347)
Shenzhen Stock Exchange · China · prices in CNY · close of 20 Oct 2026
Key indicators
| Last close | CNY 51.80 |
|---|---|
| 52-week range | 35.47 – 67.65 |
| Return, 1 month / 3 months | −1.9% / −0.2% |
| Return, 1 year / 3 years | −12.4% / −22.1% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 48.1% |
| Worst drawdown (1 year) | -45.7% |
| Average daily value traded | 913.54M CNY |
| Dividend yield | 0.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hangzhou Tigermed Consulting is a contract research organisation that helps pharmaceutical, biotechnology and medical device companies develop new treatments. It provides clinical trial services, including trial design and management, data management, statistical analysis, regulatory affairs and medical writing, along with laboratory and related support work. Its customers are drug developers and healthcare companies that outsource parts of their research and development. The company is based in Hangzhou, China, and serves clients in its home market and overseas.
On this site Hangzhou Tigermed Consulting appears as a stock on the Shenzhen Stock Exchange (China), code 300347, with prices in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hangzhou Tigermed Consulting (300347) trades on the Shenzhen Stock Exchange in China. It last closed at CNY 51.80 on 20 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 471 of 2,821 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.4% and over the last three months it fell 0.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shenzhen Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -1.6% | ||
| From 52-week high | -22.0% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.2% | ||
| 6-month return | -7.3% | ||
| 12-month return, skipping the last month | -10.7% | ||
| Stability (higher is calmer) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.7% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 913.54M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.2% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.6% |
|---|---|
| 1 month | −1.9% |
| 3 months | −0.2% |
| 6 months | −7.3% |
| 1 year | −12.4% |
| 3 years | −22.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 53.78 / 52.64 |
|---|---|
| Golden / death cross (60 days) | Golden, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.82 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jul 2026 | CNY 0.1260 |
| 17 Jun 2025 | CNY 0.3000 |
| 12 Jul 2024 | CNY 0.5680 |
| 7 Jul 2023 | CNY 0.5500 |
| 31 May 2022 | CNY 0.5000 |
| 1 Jun 2021 | CNY 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shenzhen Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.